02328nam 2200601 a 450 991077879370332120230421033142.01-280-19602-597866101960290-309-59835-40-585-02478-2(CKB)110986584751352(SSID)ssj0000123477(PQKBManifestationID)11143357(PQKBTitleCode)TC0000123477(PQKBWorkID)10005859(PQKB)10618493(MiAaPQ)EBC3376668(Au-PeEL)EBL3376668(CaPaEBR)ebr10056944(OCoLC)923265433(EXLCZ)9911098658475135219931027d1993 uy 0engurcn|||||||||txtccrClinical applications of mifepristone (RU 486) and other antiprogestins[electronic resource] assessing the science and recommending a research agenda /Committee on Antiprogestins: Assessing the Science, Division of Health Promotion and Disease Prevention, Institute of Medicine ; Molla S. Donaldson ... [et al.], editorsWashington, D.C. National Academy Press1993xi, 288 p. ill"Support for this project was provided by a grant from the Henry J. Kaiser Family Foundation, Menlo Park, California."--Verso T.p.Committee chairman: Leslie Z. Benet.0-309-04949-0 Includes bibliographical references and index.MifepristoneResearchAbortifacientsResearchProgesteroneAntagonistsResearchMifepristoneResearch.AbortifacientsResearch.ProgesteroneAntagonistsResearch.615/.766Benet Leslie Z96362Donaldson Molla S1506301Institute of Medicine (U.S.).Committee on Antiprogestins: Assessing the Science.Institute of Medicine (U.S.).Division of Health Promotion and Disease Prevention.MiAaPQMiAaPQMiAaPQBOOK9910778793703321Clinical applications of mifepristone (RU 486) and other antiprogestins3762829UNINA